Dr. Jing Zhang, former clinical Team Leader at the FDA's Center for Drug Review and Research (CDER), recently joined Createrna as Chief Medical Officer (CMO), where she is responsible for leading and managing the planning strategy, direction and execution of the company's clinical development programs and participating in the development of the company's overall strategy. This is another international high-end medical talent introduced by Createrna Technology after Dr. Wang Yaning, former director of Quantitative Pharmacology Review Room, Clinical Pharmacology Department, Drug Review Research Center of FDA, became the CEO of Createrna Technology in September 2021.

图1 77779193永利官网CMO张静博士

With more than 20 years of global drug development experience, Dr. Jing Zhang is a well-known chief Medical officer in the field with industry regulatory experience as well as drug development experience. Prior to joining Createrna, Dr. Jing Zhang held senior management positions at several prominent Chinese and international pharmaceutical companies. Including chief medical officer of Acon Pharmaceuticals, executive director of clinical research and development at AbbVie, Executive director of clinical research and development at Allergan and director of clinical research and development at Johnson & Johnson. Dr. Jing has also worked for more than 10 years at the Center for Drug Review and Research (CDER) of the U.S. Food and Drug Administration (FDA) as a clinical team leader and clinical reviewer, focusing on central nervous system drug reviews and participating in the review and marketing approval of several important central nervous system drug NDAs. In addition, Dr. Zhang received a Ph.D. in physiology from the United States Military Medical University, engaged in medical research at the National Institutes of Health (NIH) for five years and published several articles, completed residency training at the University of Chicago and practiced medicine for many years, and is licensed as a medical practitioner in the United States.

Createrna, a branch of Wuhan Qirui Technology Group, has been focusing on innovative drug research and development since 2004. After 18 years of continuous innovation and research, the company is currently researching more than 20 projects, including 4 projects in the clinical research stage and 4 projects about to enter the clinical research stage. Several pipeline projects are at the international advanced level. The joining of Dr. Zhang Jing will definitely accelerate the industrialization and internationalization process of the company's innovative achievements, and make the company become a world-class innovative pharmaceutical company with international competitiveness in the segmentation field as soon as possible.